Your browser doesn't support javascript.
loading
Murine model of steroid-resistant neutrophilic bronchial asthma as an attempt to simulate human pathology.
Shilovskiy Igor, P; Nikolskii Aleksandr, A; Kovchina Valeriya, I; Vishniakova Lyudmila, I; Yumashev Kirill, V; Barvinskaia Ekaterina, D; Kaganova Mariya, M; Korneev Artem, V; Turenko Vladislav, N; Brylina Vera, E; Petukhova Olga, A; Kudlay Dmitry, A; Khaitov Musa, R.
Afiliação
  • Shilovskiy Igor P; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation. Electronic address: ip.shilovsky@nrcii.ru.
  • Nikolskii Aleksandr A; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation.
  • Kovchina Valeriya I; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation.
  • Vishniakova Lyudmila I; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation.
  • Yumashev Kirill V; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation; Moscow State Academy of Veterinary Medicine and Biotechnology - MVA named after K.I. Skryabin of the Ministry of Agriculture of the Russian Federation, 109472 Moscow, Ru
  • Barvinskaia Ekaterina D; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation.
  • Kaganova Mariya M; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation; Moscow State Academy of Veterinary Medicine and Biotechnology - MVA named after K.I. Skryabin of the Ministry of Agriculture of the Russian Federation, 109472 Moscow, Ru
  • Korneev Artem V; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation; Moscow State Academy of Veterinary Medicine and Biotechnology - MVA named after K.I. Skryabin of the Ministry of Agriculture of the Russian Federation, 109472 Moscow, Ru
  • Turenko Vladislav N; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119991 Moscow, Russian Federation.
  • Brylina Vera E; Moscow State Academy of Veterinary Medicine and Biotechnology - MVA named after K.I. Skryabin of the Ministry of Agriculture of the Russian Federation, 109472 Moscow, Russian Federation.
  • Petukhova Olga A; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation.
  • Kudlay Dmitry A; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119991 Moscow, Russian Federation.
  • Khaitov Musa R; National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, 115522 Moscow, Russian Federation; N.I. Pirogov Russian National Research Medical University (RNRMU) of the Ministry of Health of the Russian Federation, 117997 Moscow, Russian Federation.
J Immunol Methods ; 505: 113268, 2022 06.
Article em En | MEDLINE | ID: mdl-35421364
ABSTRACT
Bronchial asthma (BA) is a heterogeneous chronic inflammatory disease of the airways. The majority of patients with mild to moderate BA develop Th2-biased eosinophilic pulmonary inflammation and respond well to corticosteroid treatment. However up to 10% of BA patients develop severe pathology, which is associated with neutrophilic inflammation and resistant to conventional corticosteroid therapy. Contrary to eosinophil-predominant airway inflammation neutrophilic BA is developed through Th1- and Th17-immune responses. However, the etiology of corticoid insensitive neutrophilic BA is still remains unclear. Therefore, in the current study we developed a mouse model of BA with predominant neutrophilic rather than eosinophilic pulmonary inflammation. BALB/c mice were immunized with the mixture of the ovalbumin allergen and Freund's adjuvant, followed by aerosol challenge with the same allergen mixed with E. coli lipopolysaccharide. As a result, mice developed the main BA manifestations production of allergen specific IgE, development of airway hyperreactivity, airway remodeling and pulmonary neutrophilic inflammation. Moreover, this pathology developed through Th1- and Th17-dependent mechanisms and mice with induced neutrophilic BA phenotype responded poorly to dexamethasone treatment, that coincide to clinical observations. The established mouse model could be useful both for studying the pathogenesis and for testing novel approaches to control neutrophilic BA.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Asma / Hiper-Reatividade Brônquica Limite: Animals / Humans Idioma: En Revista: J Immunol Methods Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia / Asma / Hiper-Reatividade Brônquica Limite: Animals / Humans Idioma: En Revista: J Immunol Methods Ano de publicação: 2022 Tipo de documento: Article